HU6
| |
| |
CAS | 2231311-68-3 |
PubChem CID | |
C11H9N5O7 | |
323.22 g·mol−1 | |
3D | |
|
HU6(5-((2,4-二硝基苯氧基)
合成
[參考 文獻
[- ^ US20190337903A1,Khan, Shaharyar,「Novel Phenyl Derivatives」
- ^ Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen. Clinical Trial Landscape in NASH. Clinical Gastroenterology and Hepatology. 2023-07, 21 (8): 2001–2014 [2024-02-23]. doi:10.1016/j.cgh.2023.03.041. (
原始 內容存 檔於2024-04-20) (英語 ). - ^ Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J. Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet Gastroenterology & Hepatology. 2023-12, 8 (12): 1094–1105 [2024-02-23]. doi:10.1016/S2468-1253(23)00198-X. (
原始 內容存 檔於2024-05-25) (英語 ). - ^ Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments. Yahoo Finance. 2023-11-15 [2024-02-23]. (
原始 內容存 檔於2023-12-03) (美國 英語 ). - ^ CN110167918B,S·M·
克 漢 ,「Novel Phenyl Derivatives」 - ^ US8003625B2,Matteucci, Mark & Jian-Xin Duan,「Phosphoramidate alkylator prodrugs」